Cumberland Pharmaceuticals Inc., based in Nashville, Tennessee, is a unique and thriving specialty pharmaceutical company that specializes in improving and sustain patient’s health. The company, represented by the ticker symbol CPIX on the NASDAQ Global Select Market, has a distinguished portfolio that covers a spectrum of different therapeutic categories.
Cumberland was built around a core business model that is focused on acquiring, developing, and commercializing branded prescription products designed for hospital acute care and gastroenterology. Furthermore, the company selectively pursues opportunities in other therapeutic areas as well. Currently, Cumberland has several marketed products: Acetadote® (acetylcysteine) Injection, Caldolor® (ibuprofen) Injection, Kristalose® (lactulose) for Oral Solution, Omeclamox-Pak®, Vaprisol® (conivaptan) Injection, Vibativ® (telavancin), and RediTrex® (methotrexate) Injection.
In addition to these products, Cumberland Pharmaceuticals also has a number of products in the developmental stage. By continuously developing and purchasing these intellectual properties, Cumberland Pharmaceuticals can develop a broad portfolio. It is through this variety of products that the company can grow and expand, serving both patients and healthcare professionals across the nation and in select international markets.
The company is led by a strategic executive team, guided by CEO Mr. A. J. Kazimi. Under his leadership, Cumberland has always been committed to delivering innovative products that improve quality of care for patients. That dedication has earned Cumberland Pharmaceuticals a reputation for excellence in the healthcare industry.
Financially, Cumberland Pharmaceuticals is a solid and secure company, consistently showing a trend of revenue and pipeline growth. The company has established a history of profitability, underscoring their effectiveness at managing operations while making strategic investments in the future.
Beyond its offerings of pharmaceutical products, Cumberland's corporate culture stands out for its high principles and commitment to stakeholders. The company believes in maintaining a healthy balance between its financial goals and its social responsibilities. This includes ensuring patient safety, investing in research and development, respecting its employees, and contributing to society in broader ways.
To sum up, Cumberland Pharmaceuticals Inc. is a reliable and forward-thinking company in the pharmaceutical industry, committed to developing and providing advanced medical solutions to improve patient health. Their dedication to excellence in their product portfolio, strategic business model, and responsible corporate culture have set them apart as a leader in their field.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Cumberland Pharmaceuticals (NASDAQ:CPIX) stock recently crossed above its 200-day moving average, reaching $8.34 before closing at $7.94, despite trading down 3.2% on the day. This technical move comes amidst negative analyst sentiment, with a "Sell" consensus and a "sell (D-)" rating reiterated by Weiss Ratings. The company also reported weaker-than-expected quarterly results, missing revenue and EPS estimates.
Cumberland Pharmaceuticals (NASDAQ:CPIX) saw its stock price climb above its 200-day moving average, reaching $6.74 before closing at $6.64, despite its long-term average being $5.48. This technical gain comes amidst negative analyst sentiment, with a consensus "Sell" rating and a reaffirmed "sell (D-)" from Weiss Ratings. The company also reported a significant quarterly loss, missing revenue and EPS estimates.
Cumberland Pharmaceuticals (Nasdaq: CPIX) has announced a special cash dividend of $1.50 per share, payable on July 31, 2026, to shareholders of record as of July 10, 2026. This decision follows a strategic transaction with Apotex Health, which provided Cumberland with $100 million in cash. The company also authorized a $5 million share repurchase program and will continue to focus on developing its clinical pipeline, including ifetroban for rare diseases like Duchenne Muscular Dystrophy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis, and Cancer Metastasis.
Cumberland Pharmaceuticals (NASDAQ:CPIX) shares recently crossed above their 200-day moving average, trading as high as $8.50 before closing at $6.69, while the 200-day average was $5.27. Despite this, analyst sentiment remains negative with a consensus "Sell" rating, and the company reported a quarterly loss and revenue significantly below estimates. Institutional investors have made some adjustments to their holdings, with several funds increasing their stakes.
Cumberland Pharmaceuticals (NASDAQ:CPIX) shares surpassed their 200-day moving average, reaching $7.87 before settling at $7.65, despite a lower 200-day average of $5.04. This rise occurs amidst negative analyst sentiment, with Weiss Ratings maintaining a "sell" and Wall Street Zen downgrading to "hold," alongside disappointing quarterly results showing an adjusted loss of $0.20 per share and revenue significantly below estimates. The company also recently declared a $1.50 dividend.
Cumberland Pharmaceuticals (NASDAQ:CPIX) shares recently surpassed their 200-day moving average, trading as high as $8.15 before settling at $7.96. Despite this technical indicator, analyst sentiment remains largely negative, with several firms issuing "sell" or "hold" ratings. The company also reported a disappointing quarter, missing revenue and earnings estimates, reinforcing concerns about its financial performance.
Cumberland Pharmaceuticals (CPIX) stock declined slightly after a strong multi-month run, despite a significant strategic pivot. The company recently completed a $100 million divestiture and issued a $1.50 per share special dividend, repositioning itself as a cash-rich, development-focused biotech. While Q2 2026 showed operating and net losses, the focus has shifted from near-term earnings to balance sheet strength and clinical execution, particularly with its ifetroban programs.
Cumberland Pharmaceuticals (CPIX) stock declined by 2.8% today, despite a significant strategic pivot. The company recently completed a $100 million divestiture and issued a $1.50 per share special dividend, transforming it into a cash-rich, development-focused biotech. While Q2 2026 showed operating and net losses, the new focus is on balance sheet strength and clinical execution of its ifetroban programs, with management projecting over five years of financial runway.
Cumberland Pharmaceuticals (NASDAQ:CPIX) reported a quarterly loss of $0.20 per share, missing analyst estimates. The company closed its Apotex transaction for $100 million and declared a special dividend of $1.50 per share, pivoting to focus on its ifetroban development pipeline. Despite the strategic shift to a development-stage biopharmaceutical company, analysts maintain a "Sell" rating on the stock.
Cumberland Pharmaceuticals (CPIX) reported a net loss of $4.1 million and net revenues of $166,458 for the second quarter of 2026, leading to a $0.27 loss per share. This follows a strategic transaction where Apotex Health acquired Cumberland’s FDA-approved brand portfolio for $100 million in cash, prompting Cumberland to declare a special cash dividend of $1.50 per share. Despite the loss, Cumberland retains late-stage development candidates, including four Phase 2 clinical programs.